Vaccine candidates for hantavirus remain confined to preclinical animal studies or early Phase 1 human trials, with no candidates advancing to Phase 3 efficacy testing or regulatory review timelines that could yield licensure by the end of 2026. Recent mRNA and DNA platforms tested against strains such as Andes and Hantaan viruses have shown promising neutralizing antibody responses in rodent and limited human models, yet development faces standard multi-year hurdles for safety, manufacturing scale-up, and field trials amid the virus's low incidence and regional strain diversity. Trader consensus at 95.5% probability for no vaccine reflects these established timelines from official surveillance and research updates, though an unprecedented surge in cases prompting emergency use authorization could theoretically compress schedules.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% chance
$135,595 Vol.
$135,595 Vol.
Dec 31, 2026
5% chance
$135,595 Vol.
$135,595 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates for hantavirus remain confined to preclinical animal studies or early Phase 1 human trials, with no candidates advancing to Phase 3 efficacy testing or regulatory review timelines that could yield licensure by the end of 2026. Recent mRNA and DNA platforms tested against strains such as Andes and Hantaan viruses have shown promising neutralizing antibody responses in rodent and limited human models, yet development faces standard multi-year hurdles for safety, manufacturing scale-up, and field trials amid the virus's low incidence and regional strain diversity. Trader consensus at 95.5% probability for no vaccine reflects these established timelines from official surveillance and research updates, though an unprecedented surge in cases prompting emergency use authorization could theoretically compress schedules.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$135,595End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates for hantavirus remain confined to preclinical animal studies or early Phase 1 human trials, with no candidates advancing to Phase 3 efficacy testing or regulatory review timelines that could yield licensure by the end of 2026. Recent mRNA and DNA platforms tested against strains such as Andes and Hantaan viruses have shown promising neutralizing antibody responses in rodent and limited human models, yet development faces standard multi-year hurdles for safety, manufacturing scale-up, and field trials amid the virus's low incidence and regional strain diversity. Trader consensus at 95.5% probability for no vaccine reflects these established timelines from official surveillance and research updates, though an unprecedented surge in cases prompting emergency use authorization could theoretically compress schedules.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$135,595End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Vaccine candidates for hantavirus remain confined to preclinical animal studies or early Phase 1 human trials, with no candidates advancing to Phase 3 efficacy testing or regulatory review timelines that could yield licensure by the end of 2026. Recent mRNA and DNA platforms tested against strains such as Andes and Hantaan viruses have shown promising neutralizing antibody responses in rodent and limited human models, yet development faces standard multi-year hurdles for safety, manufacturing scale-up, and field trials amid the virus's low incidence and regional strain diversity. Trader consensus at 95.5% probability for no vaccine reflects these established timelines from official surveillance and research updates, though an unprecedented surge in cases prompting emergency use authorization could theoretically compress schedules.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions